C1 inhibitor administration in pediatric patients with hereditary angioedema: patient compliance with intravenous therapy

Adherence in a pediatric population can be a barrier to therapy. Here we report compliance, safety, efficacy and QoL outcomes in patients aged 6-11years who received intravenous (IV) C1-INH for routine prevention of angioedema attacks.

Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: K. Jacobson, D. Soteres, S. Nieto-Martinez, D. Moldovan, I. Martinez-Saguer, M. Vardi, J. Baptista, E. Aygoren-Pursun Tags: P164 Source Type: research